| Project/Area Number |
26670183
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Experimental pathology
|
|---|
| Research Institution | Keio University |
|---|
Principal Investigator |
|
|---|
| Research Collaborator |
Kitabayashi Isho 国立がん研究センター, 研究所, 造血腫瘍分野長
Kimohara Yoshihiro 熊本大学, 大学院医学研究科細胞病理学, 准教授
Taku syuichiro 熊本大学, 大学院医学研究科脳神経外科学, 講師
Akita Hirotoshi 北海道大学, 大学院医学研究科腫瘍内科学, 教授
Yagita Hideo 順天堂大学, 医学部免疫学, 先任准教授
|
|---|
| Project Period (FY) |
2014-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | 腫瘍代謝 / 癌 / 代謝 / 免疫 / IDH(R132H) |
|---|
| Outline of Final Research Achievements |
I focused the role of most notable cancer metabolic pathway, IDH1/2 mutation in gliomas on tumor immunogenic phenotypes, I found that IDH1/2 in glioma cells contribute to generation of immunosuppressive microenvironments, which are manifested by the infiltration of M2 macrophages, MDSCs, and PD-1-positive T cells with transformation of PD-L1-positive glioma cells from PD-L1-bnegative ones. Thus, IDH-1/2 mutation triggers "inflamed phanotypes" of gliomas, and our study provides scientific rationale that immunochenckpoint blackade may be useful for targeting IDH-mutated tumors.
|
